I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Steven M. Fruchtman net worth and biography

Steven Fruchtman Biography and Net Worth

Insider of Onconova Therapeutics

Dr. Fruchtman joined Onconova in January 2015 as Chief Medical Officer. He was promoted to President in July 2018 and to CEO in January 2019. He has extensive experience in large and small biopharmaceutical companies and has led successful clinical development programs while serving in senior positions at Ortho Biotech Products, Novartis, Allos Therapeutics, Spectrum Pharmaceuticals and Syndax Pharmaceuticals.

Previously, Dr. Fruchtman was on the faculty of the Mount Sinai School of Medicine and the Director of the Stem Cell Transplantation and Myeloproliferative Disorder Programs at Mount Sinai Hospital in New York City. He is an author of more than 170 lectures, presentations, books, chapters, and abstracts and serves as an external reviewer for multiple medical journals.

Dr. Fruchtman received his medical degree from New York Medical College with the distinction of membership in the Alpha Omega Alpha honorary medical fraternity.

What is Steven M. Fruchtman's net worth?: The estimated net worth of Steven M. Fruchtman is at least $0.00 as of February 16th, 2021. Dr. Fruchtman owns 236,226 shares of Onconova Therapeutics stock worth more than $0 as of December 2nd. This net worth approximation does not reflect any other investments that Dr. Fruchtman may own. Additionally, Dr. Fruchtman receives a salary of $907,860.00 as Insider at Onconova Therapeutics. Learn More about Steven M. Fruchtman's net worth.
How old is Steven M. Fruchtman?: Dr. Fruchtman is currently 73 years old. There are 1 older executives and no younger executives at Onconova Therapeutics. Learn More on Steven M. Fruchtman's age.
What is Steven M. Fruchtman's salary?: As the Insider of Onconova Therapeutics, Inc., Dr. Fruchtman earns $907,860.00 per year. Learn More on Steven M. Fruchtman's salary.
How do I contact Steven M. Fruchtman?: The corporate mailing address for Dr. Fruchtman and other Onconova Therapeutics executives is 375 PHEASANT RUN, NEWTOWN PA, 18940. Onconova Therapeutics can also be reached via phone at (267) 759-3680 and via email at [email protected]. Learn More on Steven M. Fruchtman's contact information.
Has Steven M. Fruchtman been buying or selling shares of Onconova Therapeutics?: Steven M. Fruchtman has not been actively trading shares of Onconova Therapeutics within the last three months. Most recently, on Tuesday, September 28th, Steven M. Fruchtman bought 2,381 shares of Onconova Therapeutics stock. The stock was acquired at an average cost of $4.20 per share, with a total value of $10,000.20. Learn More on Steven M. Fruchtman's trading history.
Who are Onconova Therapeutics' active insiders?: Onconova Therapeutics' insider roster includes Steven Fruchtman (Insider), James Marino (Director), and Abraham Oler (SVP). Learn More on Onconova Therapeutics' active insiders.

Steven M. Fruchtman Insider Trading History at Onconova Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/28/2021	Buy	2,381	$4.20	$10,000.20
2/16/2021	Buy	20,000	$1.00	$20,000.00	236,226
11/25/2020	Buy	40,000	$0.26	$10,400.00	216,226
5/19/2020	Buy	26,800	$0.37	$9,916.00
11/25/2019	Buy	149,000	$0.20	$29,800.00	149,426

Steven M. Fruchtman Buying and Selling Activity at Onconova Therapeutics

Onconova Therapeutics Company Overview

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Today's Range

Now: N/A

50 Day Range

MA: $0.85

$0.67

$1.01

2 Week Range

Now: N/A

Volume

1,281,800 shs

Average Volume

96,681 shs

Market Capitalization

$20.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

Urgent Briefing: Why Wyoming is vital for a 2025 AI portfolio

From Weiss Ratings | Ad

We have a truly special way for you to gain access to all this information. For one day only … this Black Friday (Cyber Monday) … we are offering an opportunity to score access to this wealth of information … for just $19.

You read that correctly — just $19. This offer is limited to Black Friday (Cyber Monday) ONLY

Steven Fruchtman Biography and Net Worth

What is Steven M. Fruchtman's net worth?

How old is Steven M. Fruchtman?

What is Steven M. Fruchtman's salary?

How do I contact Steven M. Fruchtman?

Has Steven M. Fruchtman been buying or selling shares of Onconova Therapeutics?

Who are Onconova Therapeutics' active insiders?